ENTA - Enanta Pharmaceuticals Inc
IEX Last Trade
12.91
-0.110 -0.852%
Share volume: 111,336
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$13.02
-0.11
-0.85%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-08-08 | 2022-11-23 | 2023-02-08 | 2023-05-09 | 2023-08-08 | 2023-11-22 | 2024-02-08 | 2024-05-08 | |
| Assets | |||||||||
| Total Assets | 385.214 M | 375.410 M | 347.534 M | 326.445 M | 495.169 M | 462.275 M | 428.499 M | 413.557 M | |
| Current Assets | 313.035 M | 311.713 M | 283.704 M | 271.137 M | 448.465 M | 422.791 M | 390.303 M | 351.029 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 11.540 M | 13.445 M | 17.946 M | 14.484 M | 17.071 M | 13.263 M | 13.245 M | 10.932 M | |
| Short Term Investments | 11.540 M | 13.445 M | 17.946 M | 14.484 M | 17.071 M | 13.263 M | 13.245 M | 10.932 M | |
| Total Receivables | 48.207 M | 49.036 M | 51.288 M | 46.569 M | 44.809 M | 39.618 M | 39.907 M | 39.787 M | |
| Current Cash | 253.288 M | 249.232 M | 214.470 M | 210.084 M | 386.585 M | 369.910 M | 337.151 M | 300.310 M | |
| Total Non-current Assets | 72.179 M | 63.697 M | 63.830 M | 55.308 M | 46.704 M | 39.484 M | 38.196 M | 62.528 M | |
| Property Plant Equipment | 4.588 M | 6.173 M | 8.682 M | 11.050 M | 12.014 M | 11.919 M | 12.119 M | 15.479 M | |
| Other Assets | 703.000 K | 696.000 K | 701.000 K | 696.000 K | 830.000 K | 803.000 K | 765.000 K | 187.000 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 385.214 M | 375.410 M | 347.534 M | 326.445 M | 495.169 M | 462.275 M | 428.499 M | 413.557 M | |
| Total liabilities | 45.685 M | 52.653 M | 45.274 M | 55.647 M | 255.927 M | 244.117 M | 235.192 M | 246.020 M | |
| Total current liabilities | 23.035 M | 29.827 M | 23.001 M | 32.166 M | 68.189 M | 62.787 M | 62.407 M | 54.608 M | |
| Accounts Payable | 1.245 M | 6.000 M | 4.352 M | 11.761 M | 7.932 M | 4.097 M | 9.326 M | 6.726 M | |
| Other liabilities | 441.000 K | 454.000 K | 414.000 K | 408.000 K | 165.405 M | 160.092 M | 152.261 M | 148.000 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 441.000 K | 454.000 K | 414.000 K | 408.000 K | 165.405 M | 160.092 M | 152.261 M | 148.000 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 339.529 M | 322.757 M | 302.260 M | 270.798 M | 239.242 M | 218.158 M | 193.307 M | 167.537 M | |
| Common stock | 20.710 M | 20.763 M | 20.816 M | 21.035 M | 21.054 M | 20.971 M | 21.088 M | 21.167 M | |
| Retained earnings | -46.831 M | -73.179 M | -102.165 M | -139.823 M | -178.888 M | -206.995 M | -240.402 M | -271.559 M |